Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of subcutaneous bioresorbable afamelanotide implants in erythropoietic protoporphyria
2009-011018-51Phase 3Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Apr 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in erythropoietic protoporphyria (EPP) comparing Afamelanotide implant with Placebo implant (2 arms). Primary endpoints: Reduction in severity of phototoxic reactions and Reduction in number of phototoxic reactions. Started Apr 2009; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on 2009-011018-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011018-51.